Spectral flow cytometry has become an essential tool in multiparameter cell analysis. This advancement has led to the ability to leverage more parameters to look deeper into cellular subsets and integrate the results with high performance cell sorting. The FP7000 Spectral Cell Sorter from Sony Biotechnology enables researchers to seamlessly transition multicolor panels from cell analysis to cell sorting. The data presented in this webinar will highlight how the matched design of the two systems enables efficient operation. We will describe the design of 20+ color panels, complete detailed analysis of results using the ID7000™ Spectral Cell Analyzer, and progress to sort up to six subsets of interest using the FP7000 Cell Sorter. No panel optimization or redesign is required, saving time and reagents, and accelerating research.

Key Learning Objectives:

  • Learn how to optimize high-parameter experiments on the ID7000 Spectral Cell Analyzer and transfer them to the FP7000 Spectral Cell Sorter to purify target cell subsets from heterogenous populations.
  • Gain an understanding of the FP7000 software’s guided workflows and advanced options that enable a streamlined setup of simple and complex experiments.

 

Who should attend

This webinar will provide insights to researchers who are new to sorting or who want to learn more about how to set up sorting experiments in the areas of cell biology, immunology, and microbiology.

 

Speakers

Portrait of Andy Draghi, PhDAndy Draghi, PhD
Field Applications Scientist
Sony Biotechnology

Andy Draghi is currently a Field Applications Scientist at Sony Biotechnology and is passionate about helping researchers improve their flow cytometry approaches by providing top-level consultative support and guidance, from sample to solution. Prior to joining Sony, Andy has held the position of Field Application Scientist at another Life Science research provider, working in the high parameter segment, and prior to that, as a Research Scientist in the Early Clinical Development group at a pharmaceutical company. He completed his post-doctoral training at the NEAG Cancer Center (Department of Immunology), University of Connecticut Health Center and at the Connecticut Children’s Medical Center. Andy received his Ph.D. from the University of Connecticut where he studied molecular characterization of novel Chlamydia-like bacteria.